WHO ICTRP trial
A randomized, double-blind, adjustable-dose, parallel-group study of mosapramine…
JPRN-UMIN000028305 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000028305 |
|---|---|
| Public title | A randomized, double-blind, adjustable-dose, parallel-group study of mosapramine or aripiprazole for the treatment of Anxiety-Depressed Attack. |
| Scientific title | A randomized, double-blind, adjustable-dose, parallel-group study of mosapramine or aripiprazole for the treatment of Anxiety-Depressed Attack. - A randomized, double-blind, parallel-group study of mosapramine or aripiprazole for the treatment of Anxiety-Depressed Attack. |
| Primary sponsor | Warakukai Incorporated Medical Institution |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not applicable |
| Countries | Japan |
| Conditions | Anxious-depressive |
| Interventions | Mosapramine (in range of 200 to 1000mg / day) was administered orally, in devided powder, once a day at bedtime. Mosapramine was initiated at 200mg / day and administered in accordance with subject's health state. Aripiprazole (in range of… |
| Registration date | Mar 31, 2019 |
| Target size | 40 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: